<DOC>
	<DOCNO>NCT00466089</DOCNO>
	<brief_summary>A phase II , multicenter , randomize trial 3D Radiotherapy versus 3D Radiotherapy erlotinib ( Tarceva® ) patient localized-unresectable ( IA-IIIB ) non-small cell lung cancer non susceptible chemotherapy treatment , compare safety toxicity profile , progression-free survival arm treatment ( 3D Radiotherapy versus 3D Radiotherapy + erlotinib ) patient receive previous chemotherapy .</brief_summary>
	<brief_title>Study 3D Radiotherapy With Without Erlotinib ( Tarceva® ) Patients With Localized Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Written inform consent prior specific procedure protocol . Histologically confirm diagnosis non small cell lung cancer . Unresectable ( IAIIIB ) nonsmall cell lung cancer . Patients non susceptible chemotherapy treatment Measurable disease accord RECIST criterion Age &gt; 18 year . ECOG performance status &lt; 2 . Adequate bone marrow , hepatic , renal respiratory function . Patients capable follow adequate therapeutic compliance accessible correct followup . Women fertile age must negative serum urine pregnancy test within 7 day prior begin treatment . Patients gender fertile age , include woman last menstruation within two previous year , must follow effective contraceptive measure . Prior chemotherapy radiotherapy . History curatively treat malignancy evidence disease within past 5 year except squamous cell skin cancer , resect cervix carcinoma . Pregnant lactating woman . Any severe disease clinical condition , , : 1 . Unstable cardiopathy despite treatment , myocardial infarction within 6 month enter study 2 . Uncontrolled active infection 3 . Uncontrolled peptic ulcer , unstable diabetes mellitus contraindication treatment corticosteroid . 4 . Autoimmune diseases . Concomitant treatment antineoplastic therapy . Prior experimental pharmacological agent within 3 week prior inclusion study . Prior treatment EGFR target therapy . Erlotinib known hypersensibility . Any radiotherapy treatment contraindication . History significant neurological psychiatric disorder , include epileptic seizure . Any significant ophthalmologic impairment eye surface ( Use contact lens recommend ) Inability take oral medication surgical procedure affect absorption imply intravenous parenteral feeding . Any underlie severe process affect ability take part study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>NSCLC , lung cancer</keyword>
	<keyword>Patients localized-unresectable ( IA-IIIB ) non-small cell lung cancer non susceptible chemotherapy treatment .</keyword>
</DOC>